Login to Your Account



Alzheimer's Candidate In Phase I

Transition Therapeutics In Potential $200M Elan Deal

By Randall Osborne


Thursday, September 28, 2006
In an uncommonly structured deal, Elan Corp. plc is backfilling its troubled pipeline with a Phase I drug candidate for Alzheimer's disease, paying Transition Therapeutics Inc. as much as $200 million - $15 million of that amount promised in the next two years - for the small-molecule AZD-103. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription